Sirolimus-eluting versus bare nitinol Stent for obstructive superficial femoral artery disease:: The SIROCCO II trial

被引:335
作者
Duda, SH
Bosiers, M
Lammer, J
Scheinert, D
Zeller, T
Tielbeek, A
Anderson, J
Wiesinger, B
Tepe, G
Lansky, A
Mudde, C
Tielemans, H
Bérégi, JP
机构
[1] Univ Med Berlin, Ctr Diagnost Radiol & Minimally Invas Therapy, Jewish Hosp Berlin, Acad Teaching Hosp,Charite, D-13347 Berlin, Germany
[2] Univ Tubingen, Dept Radiol, Tubingen, Germany
[3] Herz Zentrum Leipzig, Leipzig, Germany
[4] Herzzentrum Bad Krozingen, Dept Angiol, Bad Krozingen, Germany
[5] St Blasius Ziekenhuis, Div Vasc Surg, Dendermonde, Belgium
[6] Cordis Corp, Waterloo, Belgium
[7] Univ Vienna, Klin Radiodiagnost, Dept Angiog & Intervent Radiol, Vienna, Austria
[8] Catharina Hosp, Eindhoven, Netherlands
[9] Clin Trial Operat, Oss, Netherlands
[10] Ashford Specialist Ctr, Ashford, Australia
[11] Cardiovasc Res Fdn, Angio Core Lab, New York, NY USA
[12] Ctr Hosp Reg & Univ Lille, Hop Cardiol, Serv Radiol, F-59037 Lille, France
关键词
D O I
10.1097/01.RVI.0000151260.74519.CA
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To investigate further the safety and efficacy of the sirolimus-eluting S.M.A.R.T. Nitinol Self-expanding Stent by comparison with a bare stent in superficial femoral artery (SFA) obstructions. MATERIALS AND METHODS: This randomized, double-blind study involved 57 patients (29 in the sirolimus-eluting stent group and 28 in the bare stent group) with chronic limb ischemia and SFA occlusions (66.7%) or stenoses (average lesion length, 81.5 mm +/- 41.2). Stent implantation followed standard interventional techniques and a maximum of two stents could be implanted. The primary endpoint was the in-stent mean lumen diameter at 6 months as determined by quantitative angiography. RESULTS: Both stent types were effective in revascularizing the diseased SFA and allowing sustained patency for at least 6 months. There was no statistically significant difference between treatment groups in the in-stent mean lumen diameter at 6 months (4.94 mm +/- 0.69 and 4.76 mm +/- 0.54 mm for sirolimus-eluting and bare stent groups, respectively; P = .31). Although the diameter of the target lesion tended to be larger and percent stenosis tended to be lower with the sirolimus-eluting stent, there were no statistically significant differences between treatments in terms of any of the variables. The mean late loss values were 0.38 mm +/- 0.64 and 0.68 mm +/- 0.97 for the sirolimus-eluting stent group and the bare stent group, respectively (P = .20). The binary restenosis rates, with a cutoff of 50% at 6 months, were zero in the sirolimus-eluting stent group and 7.7% in the bare stent group (P = .49). Clinical outcomes matched angiographic outcomes with improvements in ankle-brachial index and symptoms of claudication. There was no significant difference between treatments in terms of adverse events. CONCLUSION: Although there is a trend for greater efficacy in the sirolimus-eluting stent group, there were no statistically significant differences in any of the variables.
引用
收藏
页码:331 / 338
页数:8
相关论文
共 13 条
[1]   Endovascular stenting of superficial femoral artery stenosis and occlusions: results and risk factor analysis [J].
Cheng, SWK ;
Ting, ACW ;
Wong, J .
CARDIOVASCULAR SURGERY, 2001, 9 (02) :133-140
[2]  
Cho Leslie, 2003, J Invasive Cardiol, V15, P198
[3]   A COMPARISON STUDY OF SELF-EXPANDABLE STENTS VS BALLOON ANGIOPLASTY ALONE IN FEMOROPOPLITEAL ARTERY OCCLUSIONS [J].
DO, DD ;
TRILLER, J ;
WALPOTH, BH ;
STIRNEMANN, P ;
MAHLER, F .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 1992, 15 (05) :306-312
[4]   Drug-eluting stents: Potential applications for peripheral arterial occlusive disease [J].
Duda, SH ;
Poerner, TC ;
Wiesinger, B ;
Rundback, JH ;
Tepe, G ;
Wiskirchen, J ;
Haase, KK .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2003, 14 (03) :291-301
[5]   Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease [J].
Duda, SH ;
Pusich, B ;
Richter, G ;
Landwehr, P ;
Oliva, VL ;
Tielbeek, A ;
Wiesinger, B ;
Hak, JB ;
Tielemans, H ;
Ziemer, G ;
Cristea, E ;
Lansky, A ;
Bérégi, JP .
CIRCULATION, 2002, 106 (12) :1505-1509
[6]   Drug-eluting stents in vascular intervention [J].
Fattori, R ;
Piva, T .
LANCET, 2003, 361 (9353) :247-249
[7]   A RANDOMIZED COMPARISON OF CORONARY-STENT PLACEMENT AND BALLOON ANGIOPLASTY IN THE TREATMENT OF CORONARY-ARTERY DISEASE [J].
FISCHMAN, DL ;
LEON, MB ;
BAIM, DS ;
SCHATZ, RA ;
SAVAGE, MP ;
PENN, I ;
DETRE, K ;
VELTRI, L ;
RICCI, D ;
NOBUYOSHI, M ;
CLEMAN, M ;
HEUSER, R ;
ALMOND, D ;
TEIRSTEIN, PS ;
FISH, RD ;
COLOMBO, A ;
BRINKER, J ;
MOSES, J ;
SHAKNOVICH, A ;
HIRSHFELD, J ;
BAILEY, S ;
ELLIS, S ;
RAKE, R ;
GOLDBERG, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (08) :496-501
[8]   High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty [J].
Gray, BH ;
Sullivan, TM ;
Childs, MB ;
Young, JR ;
Olin, JW .
JOURNAL OF VASCULAR SURGERY, 1997, 25 (01) :74-83
[9]   Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions [J].
Grimm, J ;
Müller-Hülsbeck, S ;
Jahnke, T ;
Hilbert, C ;
Brossmann, J ;
Heller, M .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2001, 12 (08) :935-941
[10]   Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease [J].
Jahnke, T ;
Voshage, G ;
Müller-Hülsbeck, S ;
Grimm, J ;
Heller, M ;
Brossmann, J .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2002, 13 (03) :257-266